C4 Therapeutics, Inc. (C4T) announced plans to share data from the Phase 1 dose escalation portions of the ongoing Phase 1/2 trials of CFT7455 and CFT8634. The CFT8634 Phase 1 dose escalation data has been accepted as a poster presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place from November 1 ? 4, 2023 in Dublin, Ireland.

C4T will host a company-sponsored event on December 12, 2023, to share the CFT7455 dose escalation data in relapsed/refractory multiple myeloma (R/R MM). The Phase 1/2 trial is designed to characterize safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and evidence of anti-tumor activity of CFT8634 based on RECIST 1.1 criteria. As of August 29, 2023, 32 patients were enrolled across six dose escalation cohorts using a daily dosing schedule.

The Phase 1/2 trial is designed to characterize the safety, tolerability, PK, PD and anti-tumor activity of CFT7455 in patients with R/R MM or relapsed/refractory non-Hodgkin?s lymphoma (R/R NHL). The Phase 1 dose escalation portion of the ongoing Phase 1/2 trial has utilized a 14 days on/14 days off dosing schedule within which both daily dosing and Monday/Wednesday/Friday dosing were explored. C4T has completed the Phase 1 dose escalation for CFT7455 as a monotherapy in R/R MM using a 14 days on/14 days off dosing schedule; 22 patients were enrolled across five dose escalation cohorts for this portion of the study.

Enrollment continues for the Phase 1 dose escalation evaluating CFT7455 with dexamethasone in R/R MM and as a monotherapy in R/R NHL. At a company-sponsored event on December 12, 2023, C4T plans to present Phase 1 dose escalation data that focuses on the CFT7455 monotherapy regimen in R/R MM.